Topical 0.0005% tacrolimus eye drops are a safe and effective treatment for refractory vernal keratoconjunctivitis (VKC).
Topical 0.0005% tacrolimus eye drops are a safe and effective treatment for refractory vernal keratoconjunctivitis (VKC), according to data published in Eye.
Dr A. Kheirkhah et al., Farabi Eye Hospital, Eye Research Center, Tehran University of Medical Sciences, Iran, conducted the prospective study on 20 eyes of 10 patients with refractory VKC. Patients stopped using other medications and were treated with 0.0005% tacrolimus eye drops four times daily. The outcome measures included changes in subjective symptoms, objectives symptoms post-treatment and the progression of potential complications.
Patients presented with symptoms including itching, redness, photosensitivity, foreign body sensation and mucus discharge. After treatment all symptoms demonstrated signs of improvement. Objective signs such as conjunctival hyperaemia, conjunctival papillary hypertrophy, giant papillae, limbal hypertrophy, corneal punctate epithelial erosions, and corneal pannus also showed improvement.
There were no ocular complications associated with tacrolimus and additional treatment for further relief was not necessary. The study suggests the long-term use of tacrolimus for the most effective results.
AAO 2023: Company updates from Centricity Vision CEO Rob Thornhill
November 28th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Rob Thornhill, CEO of Centricity Vision, spoke with the Ophthalmology Times team about developments in the company's ZEPTOLink IOL positioning systems.
AAO 2023: Marco A. Zarbin, MD, PhD, provides analysis of the YOSEMITE and RHINE clinical trials
November 24th 2023At this year's American Academy of Ophthalmology meeting in San Francisco, California, Marco A. Zarbin, MD, spoke with Ophthalmology Times about his team's post-hoc analysis of the YOSEMITE and RHINE clinical trials